Free daily briefing on global business news.
The drug reduced flare-ups in a broader patient population than existing COPD biologics, with U.S. approval expected in early 2027
Bloomberg / Getty Images
AstraZeneca $AZN released full results Tuesday from two Phase III trials showing its experimental drug tozorakimab reduced moderate and severe flare-ups in patients with chronic obstructive pulmonary disease, raising the prospect of significant commercial returns for the Anglo-Swedish pharmaceutical company.
Across both OBERON and TITANIA, tozorakimab reduced moderate and severe COPD exacerbations among the primary population of former smokers by 29% and 34%, respectively, against placebo added to standard inhaled care. Among a wider group that also included current smokers, the figures were 30% and 29%, the company said. The results were presented at the European Respiratory Society Congress in Barcelona and published simultaneously in the New England Journal of Medicine.
